[Skip to Content]
[Skip to Content Landing]
February 1982

Prostaglandin Infusion and Endotoxin-Induced Lung Injury

Author Affiliations

From the Department of Surgery, University of California at Davis, Sacramento.

Arch Surg. 1982;117(2):175-180. doi:10.1001/archsurg.1982.01380260045008

• The use of prostaglandins is currently undergoing clinical trials in respiratory failure accompanying sepsis. The effect of prostaglandin E1 (PGE1) and prostacyclin (PGI2) infusion on endotoxin-induced lung injury, with attention to interstitial fluid flux (QL), pulmonary vascular pressure (P[unk]), leukocytes, platelets, and release of the lysosomal enzyme β-glucuronidase, was investigated. A chronic lung lymph fistula model in sheep was used. Seven sheep alternately received Escherichia coli endotoxin and endotoxin plus PGE1 at a dosage of 1 μg/kg/min. Six sheep received PGI2 (0.2 μg/kg/min) instead of PGE1. Both PGE1 and PGI2 decreased the pulmonary hypertension and the interstitial edema produced by endotoxin primarily through their vasodilatory properties. Prostacyclin seemed to have an additional membrane-stabilizing effect. A rebound increase in QL, P[unk], and platelets occurred when PGE1 or PGI2 infusion was discontinued.

(Arch Surg 1982;117:175-180)